1. A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA. (12th June 2019) Authors: Lynch, R.C.; Smith, S.D.; Shadman, M.; Ujjani, C.S.; Kurtz, D.M.; Coye, H.; Till, B.G.; Warren, E.H.; Shustov, A.R.; Maloney, D.G.; Tseng, Y.D.; Gopal, A.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY BASELINE TUMOR BURDEN IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL. (12th June 2019) Authors: Maziarz, R.T.; Schuster, S.J.; Ericson, S.G.; Rusch, E.S.; Signorovitch, J.; Li, J.; Romanov, V.V.; Maloney, D.G.; Locke, F.L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure. (12th June 2019) Authors: Gauthier, J.; Hirayama, A.V.; Hay, K.A.; Lymp, J.; Li, D.; Sheih, A.; Purushe, J.; Pender, B.S.; Hawkins, R.M.; Vakil, A.; Phi, T.; Steinmetz, R.N.; Riddell, S.R.; Maloney, D.G.; Turtle, C.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY. (12th June 2019) Authors: Hirayama, A.V.; Gauthier, J.; Hay, K.A.; Voutsinas, J.M.; Wu, Q.; Sheih, A.; Purushe, J.; Pender, B.S.; Hawkins, R.M.; Vakil, A.; Phi, T.; Steinmetz, R.N.; Riddell, S.R.; Maloney, D.G.; Turtle, C.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil. (4th February 2013) Authors: Li, H.; Mager, D.E.; Sandmaier, B.M.; Maloney, D.G.; Bemer, M.J.; McCune, J.S. Journal: Journal of clinical pharmacology Issue: Volume 53:Number 4(2013:Apr.) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil. (6th April 2013) Authors: Li, H.; Mager, D.E.; Sandmaier, B.M.; Maloney, D.G.; Bemer, M.J.; McCune, J.S. Journal: Journal of clinical pharmacology Issue: Volume 53:Number 4(2013:Apr.) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULTS AFTER CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR‐MODIFIED T‐CELL (CAR‐T) THERAPY. (12th June 2019) Authors: Shadman, M.; Gauthier, J.; Hay, K.A.; Voutsinas, J.M.; Milano, F.; Li, A.; Hirayama, A.V.; Sorror, M.L.; Cassaday, R.D.; Till, B.G.; Gopal, A.K.; Sandmaier, B.M.; Maloney, D.G.; Turtle, C.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗